Gene expression study of host-human T-cell leukaemia virus type 1 (HTLV-1) interactions: adult T-cell leukaemia/lymphoma (ATLL).
ATLL
CXCR3
HBZ
HTLV-1
Pyroptosis
Tax
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
27
03
2023
accepted:
21
06
2023
medline:
29
8
2023
pubmed:
22
7
2023
entrez:
22
7
2023
Statut:
ppublish
Résumé
In HTLV-1-associated malignant disease, adult T-cell leukaemia/lymphoma (ATLL), the interaction of virus and host was evaluated at the chemokines gene expression level. Also, IL-1β and Caspase-1 expressions were evaluated to investigate the importance of pyroptosis in disease development and progression. The expression of host CCR6 and CXCR-3 and the HTLV-1 proviral load (PVL), Tax, and HBZ were assessed in 17 HTLV-1 asymptomatic carriers (ACs) and 12 ATLL patients using the reverse transcription-quantitative polymerase chain reaction (RT-qPCR), TaqMan method. Moreover, RT-qPCR, SYBR Green assay were performed to measure Caspase-1 and IL-1β expression. HTLV-1-Tax did not express in 91.5% of the ATLLs, while HBZ was expressed in all ATLLs. The expression of CXCR3 dramatically decreased in ATLLs compared to ACs (p = 0.001). The expression of CCR6 was lower in ATLLs than ACs (p = 0.04). The mean of PVL in ATLL patients was statistically higher than ACs (p = 0.001). Furthermore, the expression of the IL-1β between ATLLs and ACs was not statistically significant (p = 0.4). In contrast, there was a meaningful difference between Caspase-1 in ATLLs and ACs (p = 0.02). The present study indicated that in the first stage of ATLL malignancy toward acute lymphomatous, CXCR3 and its progression phase may target the pyroptosis process. Mainly, HBZ expression could be a novel therapeutic target.
Sections du résumé
BACKGROUND
BACKGROUND
In HTLV-1-associated malignant disease, adult T-cell leukaemia/lymphoma (ATLL), the interaction of virus and host was evaluated at the chemokines gene expression level. Also, IL-1β and Caspase-1 expressions were evaluated to investigate the importance of pyroptosis in disease development and progression.
METHODS AND RESULTS
RESULTS
The expression of host CCR6 and CXCR-3 and the HTLV-1 proviral load (PVL), Tax, and HBZ were assessed in 17 HTLV-1 asymptomatic carriers (ACs) and 12 ATLL patients using the reverse transcription-quantitative polymerase chain reaction (RT-qPCR), TaqMan method. Moreover, RT-qPCR, SYBR Green assay were performed to measure Caspase-1 and IL-1β expression. HTLV-1-Tax did not express in 91.5% of the ATLLs, while HBZ was expressed in all ATLLs. The expression of CXCR3 dramatically decreased in ATLLs compared to ACs (p = 0.001). The expression of CCR6 was lower in ATLLs than ACs (p = 0.04). The mean of PVL in ATLL patients was statistically higher than ACs (p = 0.001). Furthermore, the expression of the IL-1β between ATLLs and ACs was not statistically significant (p = 0.4). In contrast, there was a meaningful difference between Caspase-1 in ATLLs and ACs (p = 0.02).
CONCLUSIONS
CONCLUSIONS
The present study indicated that in the first stage of ATLL malignancy toward acute lymphomatous, CXCR3 and its progression phase may target the pyroptosis process. Mainly, HBZ expression could be a novel therapeutic target.
Identifiants
pubmed: 37480512
doi: 10.1007/s11033-023-08626-8
pii: 10.1007/s11033-023-08626-8
doi:
Substances chimiques
Caspase 1
EC 3.4.22.36
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7479-7487Subventions
Organisme : Mashhad University of Medical Sciences
ID : MUMS 971184
Organisme : Mashhad University of Medical Sciences
ID : MUMS 981133
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Gessain A, Cassar O (2012) Epidemiological aspects and World distribution of HTLV-1 infection. Front Microbiol 3:388. https://doi.org/10.3389/fmicb.2012.00388
doi: 10.3389/fmicb.2012.00388
pubmed: 23162541
pmcid: 3498738
Ahmadi Ghezeldasht S, Shirdel A, Assarehzadegan MA, Hassannia T, Rahimi H, Miri R et al (2013) Human T lymphotropic virus type I (HTLV-I) oncogenesis: molecular aspects of virus and host interactions in pathogenesis of adult T cell Leukemia/Lymphoma (ATL). Iran J Basic Med Sci 16(3):179–195
pubmed: 24470860
pmcid: 3881257
Mota TM, Jones RB (2019) HTLV-1 as a model for virus and host coordinated immunoediting. Front Immunol 10:2259. https://doi.org/10.3389/fimmu.2019.02259
doi: 10.3389/fimmu.2019.02259
pubmed: 31616431
pmcid: 6768981
Lemoine FJ, Wycuff DR, Marriott SJ (2001) Transcriptional activity of HTLV-I Tax influences the expression of marker genes associated with cellular transformation. Dis Markers 17(3):129–137. https://doi.org/10.1155/2001/263567
doi: 10.1155/2001/263567
pubmed: 11790876
Saito M, Matsuzaki T, Satou Y, Yasunaga J, Saito K, Arimura K et al (2009) In vivo, expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology 6:19. https://doi.org/10.1186/1742-4690-6-19
doi: 10.1186/1742-4690-6-19
pubmed: 19228429
pmcid: 2653460
Ahmadi Ghezeldasht S, Blackbourn DJ, Mosavat A, Rezaee SA (2023) Pathogenicity and virulence of human T lymphotropic virus type-1 (HTLV-1) in oncogenesis: adult T-cell leukaemia/lymphoma (ATLL). Critical Reviews in Clinical Laboratory Sciences. :1–23. https://doi.org/10.1080/10408363.2022.2157791
Griffith JW, Sokol CL, Luster AD (2014) Chemokines and chemokine receptors: positioning cells for host defence and immunity. Annu Rev Immunol 32:659–702
doi: 10.1146/annurev-immunol-032713-120145
pubmed: 24655300
Tang P, Wang JM (2018) Chemokines: the past, the present and the future. Cell Mol Immunol 15(4):295–298. https://doi.org/10.1038/cmi.2018.9
doi: 10.1038/cmi.2018.9
pubmed: 29578534
pmcid: 6052843
Clark-Lewis I, Mattioli I, Gong J-H, Loetscher P (2003) Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 278(1):289–295. https://doi.org/10.1074/jbc.M209470200
doi: 10.1074/jbc.M209470200
pubmed: 12417585
Zhou YQ, Liu DQ, Chen SP, Sun J, Zhou XR, Xing C et al (2019) The role of CXCR3 in neurological Diseases. Curr Neuropharmacol 17(2):142–150. https://doi.org/10.2174/1570159x15666171109161140
doi: 10.2174/1570159x15666171109161140
pubmed: 29119926
pmcid: 6343204
Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J et al (2014) CBTRUS statistical report: primary brain and central nervous system tumours diagnosed in the United States in 2007–2011. Neuro Oncol 16(Suppl 4):iv1–63. https://doi.org/10.1093/neuonc/nou223
doi: 10.1093/neuonc/nou223
pubmed: 25304271
pmcid: 4193675
Rafatpanah H, Felegari M, Azarpazhooh MR, Vakili R, Rajaei T, Hampson I et al (2017) Altered expression of CXCR3 and CCR6 and their ligands in HTLV-1 carriers and HAM/TSP patients. J Med Virol 89(8):1461–1468. https://doi.org/10.1002/jmv.24779
doi: 10.1002/jmv.24779
pubmed: 28206670
Hashikawa K, Yasumoto S, Nakashima K, Arakawa F, Kiyasu J, Kimura Y et al (2014) Microarray analysis of gene expression by the microdissected epidermis and dermis in mycosis fungoides and adult T-cell leukaemia/lymphoma. Int J Oncol 45(3):1200–1208. https://doi.org/10.3892/ijo.2014.2524
doi: 10.3892/ijo.2014.2524
pubmed: 24970722
Naito T, Yasunaga JI, Mitobe Y, Shirai K, Sejima H, Ushirogawa H et al (2018) Distinct gene expression signatures induced by viral transactivators of different HTLV-1 subgroups that confer a different risk of HAM/TSP. Retrovirology 15(1):72. https://doi.org/10.1186/s12977-018-0454-x
doi: 10.1186/s12977-018-0454-x
pubmed: 30400920
pmcid: 6219256
Yamazaki T, Yang XO, Chung Y, Fukunaga A, Nurieva R, Pappu B et al (2008) CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol 181(12):8391–8401
doi: 10.4049/jimmunol.181.12.8391
pubmed: 19050256
Heo YJ, Choi S-E, Lee N, Jeon JY, Han SJ, Kim DJ et al (2020) CCL20 induced by visfatin in macrophages via the NF-κB and MKK3/6-p38 signalling pathways contributes to hepatic stellate cell activation. Mol Biol Rep 47(6):4285–4293. https://doi.org/10.1007/s11033-020-05510-7
doi: 10.1007/s11033-020-05510-7
pubmed: 32418112
pmcid: 7295719
Frick VO, Rubie C, Keilholz U, Ghadjar P (2016) Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: an overview. World J Gastroenterol 22(2):833–841. https://doi.org/10.3748/wjg.v22.i2.833
doi: 10.3748/wjg.v22.i2.833
pubmed: 26811629
pmcid: 4716081
Korbecki J, Grochans S, Gutowska I, Barczak K, Baranowska-Bosiacka I (2020) CC chemokines in a tumour: a review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands. Int J Mol Sci 21(20):7619
doi: 10.3390/ijms21207619
pubmed: 33076281
pmcid: 7590012
Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y et al (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457(7225):102–106. https://doi.org/10.1038/nature07623
doi: 10.1038/nature07623
pubmed: 19122641
pmcid: 2746432
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related Inflamm Nat 454(7203):436–444
Wei X, Xie F, Zhou X, Wu Y, Yan H, Liu T et al (2022) Role of pyroptosis in inflammation and cancer. Cell Mol Immunol 19(9):971–992
doi: 10.1038/s41423-022-00905-x
pubmed: 35970871
pmcid: 9376585
Shi J, Gao W, Shao F, Pyroptosis (2017) Gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci 42(4):245–254. https://doi.org/10.1016/j.tibs.2016.10.004
doi: 10.1016/j.tibs.2016.10.004
pubmed: 27932073
Hu Y, Wang B, Li S, Yang S (2022) Pyroptosis, and its role in central nervous system disease. J Mol Biol 434(4):167379
doi: 10.1016/j.jmb.2021.167379
pubmed: 34838808
Wu Y, Zhang J, Yu S, Li Y, Zhu J, Zhang K et al (2022) Cell pyroptosis in health and inflammatory diseases. Cell death discovery 8(1):191
doi: 10.1038/s41420-022-00998-3
pubmed: 35411030
pmcid: 8995683
Derakhshan R, Mirhosseini A, Ahmadi Ghezeldasht S, Jahantigh HR, Mohareri M, Boostani R et al (2020) Abnormal vitamin D and lipid profile in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. Mol Biol Rep 47(1):631–637. https://doi.org/10.1007/s11033-019-05171-1
doi: 10.1007/s11033-019-05171-1
pubmed: 31713009
Ma G, Yasunaga J, Matsuoka M (2016) Multifaceted functions and roles of HBZ in HTLV-1 pathogenesis. Retrovirology 13:16. https://doi.org/10.1186/s12977-016-0249-x
doi: 10.1186/s12977-016-0249-x
pubmed: 26979059
pmcid: 4793531
Akbarin MM, Shirdel A, Bari A, Mohaddes ST, Rafatpanah H, Karimani EG et al (2017) Evaluation of the role of TAX, HBZ, and HTLV-1 proviral load on the survival of ATLL patients. Blood Res 52(2):106. https://doi.org/10.5045/br.2017.52.2.106
doi: 10.5045/br.2017.52.2.106
pubmed: 28698846
pmcid: 5503887
Satou Y, Matsuoka M (2012) Molecular and Cellular Mechanisms of Leukemogenesis of ATL: Emergent evidence of a significant role for HBZ in HTLV-1-Induced Pathogenesis. Leuk Res Treatment 2012:213653. https://doi.org/10.1155/2012/213653
doi: 10.1155/2012/213653
pubmed: 23198153
Yamada K, Miyoshi H, Yoshida N, Shimono J, Sato K, Nakashima K et al (2021) Human T-cell lymphotropic virus HBZ and tax mRNA expression are associated with specific clinicopathological features in adult T-cell leukaemia/lymphoma. Mod Pathol 34(2):314–326. https://doi.org/10.1038/s41379-020-00654-0
doi: 10.1038/s41379-020-00654-0
pubmed: 32973330
Vandermeulen C, O’Grady T, Wayet J, Galvan B, Maseko S, Cherkaoui M et al (2021) The HTLV-1 viral oncoproteins tax and HBZ reprogram the cellular mRNA splicing landscape. PLoS Pathog 17(9):e1009919. https://doi.org/10.1371/journal.ppat.1009919
doi: 10.1371/journal.ppat.1009919
pubmed: 34543356
pmcid: 8483338
Kobayashi N, Konishi H, Sabe H, Shigesada K, Noma T, Honjo T et al (1984) Genomic structure of HTLV (human T-cell leukaemia virus): detection of the defective genome and its amplification in MT-2 cells. Embo j 3(6):1339–1343. https://doi.org/10.1002/j.1460-2075.1984.tb01974.x
doi: 10.1002/j.1460-2075.1984.tb01974.x
pubmed: 6086318
pmcid: 557520
Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S et al (2018) CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation–a target for novel cancer therapy. Cancer Treat Rev 63:40–47
doi: 10.1016/j.ctrv.2017.11.007
pubmed: 29207310
Lane BR, King SR, Bock PJ, Strieter RM, Coffey MJ, Markovitz DM (2003) The CXC chemokine IP-10 stimulates HIV-1 replication. Virology 307(1):122–134
doi: 10.1016/S0042-6822(02)00045-4
pubmed: 12667820
Zeremski M, Dimova R, Brown Q, Jacobson IM, Markatou M, Talal AH (2009) Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis 200(11):1774–1780
doi: 10.1086/646614
pubmed: 19848607
Kawada K, Hosogi H, Sonoshita M, Sakashita H, Manabe T, Shimahara Y et al (2007) Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 26(32):4679–4688
doi: 10.1038/sj.onc.1210267
pubmed: 17297455
Bergsbaken T, Fink SL, Cookson BT (2009) Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 7(2):99–109. https://doi.org/10.1038/nrmicro2070
doi: 10.1038/nrmicro2070
pubmed: 19148178
pmcid: 2910423
Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O et al (2014) Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 505(7484):509–514. https://doi.org/10.1038/nature12940
doi: 10.1038/nature12940
pubmed: 24356306
pmcid: 4047036
Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y et al (2020) Pyroptosis: a new frontier in cancer. Biomed Pharmacother 121:109595
doi: 10.1016/j.biopha.2019.109595
pubmed: 31710896
van Montfoort N, Olagnier D, Hiscott J (2014) Unmasking immune sensing of retroviruses: interplay between innate sensors and host effectors. Cytokine Growth Factor Rev 25(6):657–668. https://doi.org/10.1016/j.cytogfr.2014.08.006
doi: 10.1016/j.cytogfr.2014.08.006
pubmed: 25240798
Chu Q, Jiang Y, Zhang W, Xu C, Du W, Tuguzbaeva G et al (2016) Pyroptosis is involved in the pathogenesis of human hepatocellular carcinoma. Oncotarget 7(51):84658–84665. https://doi.org/10.18632/oncotarget.12384
doi: 10.18632/oncotarget.12384
pubmed: 27705930
pmcid: 5356689
Wei Q, Mu K, Li T, Zhang Y, Yang Z, Jia X et al (2014) Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression. Lab Invest 94(1):52–62. https://doi.org/10.1038/labinvest.2013.126
doi: 10.1038/labinvest.2013.126
pubmed: 24166187
Sun Y, Guo Y (2018) Expression of Caspase-1 in breast cancer tissues and its effects on cell proliferation, apoptosis and invasion. Oncol Lett 15(5):6431–6435. https://doi.org/10.3892/ol.2018.8176
doi: 10.3892/ol.2018.8176
pubmed: 29725399
pmcid: 5920210
Hu B, Elinav E, Huber S, Booth CJ, Strowig T, Jin C et al (2010) Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A 107(50):21635–21640. https://doi.org/10.1073/pnas.1016814108
doi: 10.1073/pnas.1016814108
pubmed: 21118981
pmcid: 3003083